Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Paratek Pharmaceuticals to Report Third Quarter 2016 Financial Results and Provide Update on Clinical Progress on November 2, 2016

Paratek Pharmaceuticals
Posted on: 25 Oct 16

BOSTON, Oct. 24, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, announced today that it will host a conference call and live audio webcast on Wednesday, November 2, 2016 at 8:30 AM ET to report third quarter 2016 financial results and provide an update on its clinical development efforts for omadacycline for skin infections, community acquired bacterial pneumonia, and urinary tract infections. 

The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.paratekpharma.com. 

Domestic investors wishing to participate in the call should dial: 877-407-9039 and international investors should dial: 201-689-8470. The conference ID is 13648499. Investors can also access the call at http://public.viavid.com/index.php?id=121674. 

Replays of the call will be available through November 16, 2016. Domestic investors can access the replay by dialing 844-512-2921 and international investors can access the replay by dialing 412-317-6671. The PIN code to access the replay is 13648499. 

About Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethylcyclines, with broad-spectrum activity against Gram-positive, Gram-negative and atypical bacteria. In June 2016 Paratek announced positive efficacy data in a Phase 3 registration study in ABSSSI demonstrating the efficacy and safety of intravenous (IV) to oral omadacycline compared to linezolid. A Phase 3 registration study for community acquired bacterial pneumonia (CABP) comparing IV-to-oral omadacycline to IV-to-oral moxifloxacin was initiated in November 2015.  Enrollment continues on track to report top line data as early as the third quarter of 2017.  A Phase 3 registration study in ABSSSI comparing once-daily oral-only dosing of omadacycline to twice-daily oral-only dosing of linezolid was initiated in August 2016. Top line data are expected as early as the second quarter of 2017. A Phase 1b study in uncomplicated urinary tract infections (UTI) was initiated in May 2016.  Top line data from this study will be  shared in November 2016.  Omadacycline has been granted Qualified Infectious Disease Product designation and Fast Track status by the U.S. Food and Drug Administration. 

Omadacycline is a new once-daily oral and IV, well-tolerated broad spectrum antibiotic being developed for use as empiric monotherapy for patients suffering from serious community-acquired bacterial infections, such as acute bacterial skin and skin structure infections, community acquired bacterial pneumonia, urinary tract infections and other community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians. 

Paratek's second Phase 3 product candidate, sarecycline, is a well-tolerated, once-daily, oral, narrow spectrum tetracycline-derived antibiotic with potent anti-inflammatory properties for the potential treatment of acne and rosacea in the community setting. Allergan owns the U.S. rights for the development and commercialization of sarecycline. Paratek retains all ex-U.S. rights. Allergan initiated two identical Phase 3 registration studies in December 2014 for sarecycline for the treatment of moderate to severe acne vulgaris. Top line data are expected in the first half of 2017. 

For more information, visit www.paratekpharma.com.

CONTACTS:

Media Relations:     Investor Relations:

Michael Lampe     Hans Vitzthum

(484) 575-5040     LifeSci Advisors, LLC.

michael@scientpr.com     212-915-2568

For more information:
globenewswire.com/news-release/2016/10/24/882011/0/en/Paratek-Pharmaceuticals-to-Report-Third-Quarter-2016-Financial-Results-and-Provide-Update-on-Clinical-Progress-on-November-2-2016.html

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 25/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.